Former AdventHealth Celebration ER Nurse & patient, Rene Galloway, 52, recently became the first recipient in the world to have a brand-new procedure called an Endoscopic Blind Limb Reduction with Septotomy, also known as a “Candy Cane” procedure. Using repurposed surgery tools, AdventHealth Orlando Interventional Endoscopist, Dr. Kambiz Kadkhodayan, created, sketched out this new type of surgery, discussed it with Galloway and her husband and performed the first of two back-to-back surgeries in March 2023.
Candy Cane Syndrome refers to patients, like Galloway, who have undergone roux-en-y gastric bypass (RYGB) and develop significant and sometimes debilitating abdominal discomfort. Symptoms typically begin after eating and usually dissipate after vomiting.
“By suturing endoscopically and dissecting with the use of electricity, we reduced the blind pouch,” said Kadkhodayan. “That was the a-ha moment – when we realized that there was no contrast filling the blind pouch and almost all of the contrast entered into the elemental limb like we would normally expect.”
To learn more about Galloway’s journey and how the AdventHealth Center for Interventional Endoscopy team changed her life, click here.
12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
AdventHealth Celebration Team Performs First-in-World Procedure Targeting Kidney Tumor with Sound Beams
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
Podcast
Test Apple Podcast - All Episodes
Test Apple Podcast
Social Media Post
AdventHealthMD Social Media Post Test - Consumer Title
As the Official Healthcare Provider of the 2024 NASCAR Chicago Street Race, we’re thrilled to support such a memorable experience with this amazing community.
News
Clone of AdventHealth Celebration Team Performs First-in-world Procedure Targeting Kidney Tumor with Sound Beams
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Media Coverage
Consumer Title - AdventHealthMD Media Coverage Test
A summary of the article goes here. A summary of the article goes here. A summary of the article goes here. A summary of the article goes here.
News
AdventHealth Celebration Team Performs First-in-world Procedure Targeting Kidney Tumor with Sound Beams
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Video
Dr. Corbin on the gut microbiome research study
Dr. Corbin on the gut microbiome research study
News
Genetic Testing at AdventHealth Alerts Woman, Doctors to Aggressive Cancer Before it Develops
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
News
AdventHealth Clinical Research Unit Recruiting Patients with Solid Tumors Harboring MTAP Deletion for Phase I Clinical Trial
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
News
AdventHealth Research Institute conducting two studies on the impact of shift work on healthcare workers’ health
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
News
AdventHealth Celebration Successfully Performs First Robotics-assisted Cochlear Implant Procedure in Florida with the iotaSOFT® Insertion System.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
News
New England Journal of Medicine highlights Guru Sonpavde, MD’s work in new immunotherapy-chemotherapy combination improving survival for patients with advanced urothelial carcinoma
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...